CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study
University of Kansas Medical Center
Summary
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participant or legal representative is able to provide written informed prior to performing any protocol-related procedures * Is willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study * Men or women at least 18 years of age with histologically or cytologically confirmed non-small cell lung cancer * Previous history of other than lung cancer is allowed if no active treatment for that cancer within 1 year * Life expectancy of at least 6 months * De novo stage IV or recurrent NSCLC without actionable muta…
Interventions
- DrugAtezolizumab
Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
Locations (2)
- The University of Kansas Cancer Center (KUCC)Fairway, Kansas
- The University of Kansas Cancer Center, Westwood CampusKansas City, Kansas